4-Isopropyl-5,5-dimethyl-dihydro-furan-2-one | 64566-22-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: 4-Isopropyl-5,5-dimethyl-dihydro-furan-2-one
• 英文别名: 5,5-Dimethyl-4-propan-2-yloxolan-2-one
• CAS: 64566-22-9
• 化学式: C₉H₁₆O₂
• 分子量: 156.225
• InChiKey: TVWMRKUKOPAJEX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  Ethyl 3-hydroxy-3-isopropyl-4-methylpentanoate 生成 4-Isopropyl-5,5-dimethyl-dihydro-furan-2-one
  参考文献：
  名称：

  DOBREV A.; DIMITROVA B.; TCHOLAKOVA T.; IVANOW C., GODISHN. SOFIJSK. YH-T. XIM. FAK., 1975-1976(1979), 70, NO 2, 5-10

  摘要：

  DOI：

文献信息

• MORPHOLINOTHIAZOLES AS ALPHA 7 POSITIVE ALLOSTERIC MODULATORS
  申请人：Macdonald Gregor James

  公开号：US20120238561A1

  公开（公告）日：2012-09-20

  The present invention relates to morpholinothiazole derivatives and pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to positive allosteric modulators of nicotinic acetylcholine receptors, such positive allosteric modulators having the capability to increase the efficacy of nicotinic receptor agonists.

  本发明涉及吗啉噻唑衍生物及其可药用盐，它们的制备方法，含有它们的药物组合物及其在治疗中的用途。特别是涉及烟酸乙酰胆碱受体的正变构调节剂，这些正变构调节剂具有增加烟酸受体激动剂效力的能力。
• DOBREV A.; IVANOV C., SYNTHESIS, 1977, NO 8, 562-563
  作者：DOBREV A.、 IVANOV C.

  DOI：——

  日期：——
• Substituted Diaza-Spiro-[5.5]-Undecane Derivaties and Their Use as Neurokinin Antagonists
  申请人：Janssens Eduard Frans

  公开号：US20070232636A1

  公开（公告）日：2007-10-04

  This invention concerns substituted diaza-spiro-[5.5]-undecane derivatives having neurokinin antagonistic activity, in particular NK 1 antagonistic activity, a combined NK 1 /NK 2 antagonistic activity, a combined NK 1 /NK 3 antagonistic activity and a combined NK 1 /NK 2 /NK 3 antagonistic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment and/or prophylaxis of schizophrenia, emesis, anxiety and depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pre-eclampsia, nociception, pain, in particular visceral and neuropathic pain, pancreatitis, neurogenic inflammation, asthma, COPD and micturition disorders such as urinary incontinence. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1.
• US7393873B2
  申请人：——

  公开号：US7393873B2

  公开（公告）日：2008-07-01
• US7544694B2
  申请人：——

  公开号：US7544694B2

  公开（公告）日：2009-06-09